2c. Failed apnea reduction after 2–7 days – doxapram as an adjunct to methylxanthine compared to methylxanthine alone for the prevention of reintubation · prevention of reintubation
Doxapram showed no clear difference in 2c. Failed apnea reduction after 2–7 days – doxapram as an adjunct… compared with no treatment, placebo, methylxanthine (including theophylline,… (low certainty).
1 finding from 1 review
IV antibiotics: number of days on IV antibiotics · adolescents and adults with cystic fibrosis
Digital technology showed no clear difference in IV antibiotics: number of days on IV antibiotics compared with usual care (low certainty).
1 finding from 1 review
Intervention not reported
Finding 7. Patients regarded in‐person home‐based rehabilitation and telerehabilitation services as convenient and less disruptive of everyday activities.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of CAAs (up to 30 days) · people undergoing initial treatment for KD
Primary treatment with intravenous immunoglobulin (IVIG) probably leads to lower incidence of CAAs (up to 30 days) compared with acetylsalicylic acid (ASA) (moderate certainty).
1 finding from 1 review
Duration of fever · people undergoing initial treatment for KD
1 finding from 1 review
Duration of hospital stay MCID: 1 day absolute difference · people undergoing initial treatment for KD
1 finding from 1 review
Fever clearance time · people undergoing initial treatment for KD
1 finding from 1 review
Incidence of any adverse effects after treatment initiation ( · people undergoing initial treatment for KD
It is very uncertain whether primary treatment with intravenous immunoglobulin (IVIG) changes incidence of any adverse effects after treatment initiation (from 30… compared with acetylsalicylic acid (ASA) (very low certainty).
1 finding from 1 review
Length of hospital stay · people undergoing initial treatment for KD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality (all‐cause) (up to 30 days) · people undergoing initial treatment for KD
1 finding from 1 review
Duration of fever · people undergoing initial treatment for KD
1 finding from 1 review
Need for extra treatment · people undergoing initial treatment for KD
Primary treatment with intravenous immunoglobulin (IVIG) showed no clear difference in need for additional treatment (up to 30 or 60 days) compared with acetylsalicylic acid (ASA) (low certainty).
1 finding from 1 review
Length of hospital stay · people undergoing initial treatment for KD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of CAAs (up to 30 days) · people undergoing initial treatment for KD
Primary treatment with intravenous immunoglobulin (IVIG) probably leads to lower incidence of CAAs (up to 30 days) compared with different infusion regimens of IVIG (moderate certainty).
1 finding from 1 review
Proportion of participants reporting no worse than mild pain by 14 days after start of treatment · adults with cancer‐related pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at up to day 281 · hospitalised individuals with COVID‐19 (moderate to severe disease)
Remdesivir and standard care showed no clear difference in all‐cause mortality at up to day 281 compared with standard care (plus/minus placebo) (moderate certainty).
1 finding from 1 review
Admission to hospital or death within 28 days · non‐hospitalised adults with mild COVID‐19
Remdesivir and standard care probably leads to lower clinical worsening: participants admitted to hospital or deceased at… compared with standard care (plus/minus placebo) (moderate certainty).
1 finding from 1 review
Serious adverse events at up to day 28 · non‐hospitalised adults with mild COVID‐19
Remdesivir and standard care may leads to lower serious adverse events at up to day 28 compared with standard care (plus/minus placebo) (low certainty).
1 finding from 1 review
Adverse events: all grades · non‐hospitalised adults with mild COVID‐19
Remdesivir and standard care showed no clear difference in adverse events (any grade) at up to day 28 compared with standard care (plus/minus placebo) (moderate certainty).
1 finding from 1 review
All‐cause mortality at up to day 60 · hospitalised individuals with COVID‐19 (moderate to severe disease)
Remdesivir and standard care showed no clear difference in all‐cause mortality at up to day 60 compared with standard care (plus/minus placebo) (moderate certainty).
1 finding from 1 review